Investigator-Prescribed Prophylaxis of rFIX (BeneFIX®) in Children <6 Years of Age: Efficacy and Safety Outcomes.

Prophylaxis is increasingly prescribed in treatment of hemophilia. The therapeutic benefit is believed to be most significant for the youngest patients since hemophilic arthropathy may be prevented if prophylaxis is initiated prior to recurrent hemarthroses. While clinical prophylaxis data is readily available for hemophilia A, analogous data for hemophilia B is limited. A prospective clinical study of recombinant human FIX (rFIX; BeneFIX ® ) was recently completed in which the efficacy and safety of rFIX were evaluated in children Table 1. Bleeding Rate During Prophylaxis by Infusion Schedule